The failure of OV101 puts the spotlight on Ultragenyx and Roche.
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.